Rubric :   Review Articles

KEYTRUDA (pembrolizumab): expanding opportunities in the treatment of resectable non-small cell lung cancer
Т. 15, №2 (58)
Drugs used as radiosensitizers: clinical and pharmaceutical aspects and prospects (literature review)
Authors: Andrushchenko I.V. Afanasieva I.O. Т. 15, №2 (58)
Possibilities of modern visualization methods in planning radiation therapy in patients with cervical cancer
Authors: Ivankova V.S. Domina E.A. Khrulenko T.V. Baranovska L.M.... Т. 15, №2 (58)
Management strategy for gastrointestinal stromal tumors (GIST): current status and future perspectives
Authors: Kondratskyi Yu.M. Koval N.O. Kolesnyk A.V. Kozak E.O.... Т. 15, №2 (58)
Prognostic factors for successful discontinuation of tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia
Authors: Tomashevska N.Y. Kotlyarchuk K.B. Korolchuk O.S. Boyko O.I.... Т. 15, №2 (58)
Modern approaches to the treatment of advanced ovarian cancer in the 1st line therapy (PAOLA-1 study) and recurrent ovarian cancer regardless of the presence of BRCA mutations, as well as modern cytoreductive approaches (based on materials from the ESGO 2025 Congress)
Т. 15, №2 (58)
Peritoneal carcinomatosis from gastric cancer treatment perspectives. A narrative review
Authors: Pepenin M.O. Kondratskyi Y.M. Dobrzhanskyi O.Y. Kolesnyk A.V.... Т. 15, №2 (58)
Subscapular artery system flaps in head and neck reconstructive surgery: literature review and clinical experience
Authors: Fokin H.H. Kravets O.V. Т. 15, №1 (57)
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison
Т. 15, №1 (57)
Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score <1%: pooled analysis of outcomes after five years of follow-up
Т. 15, №1 (57)
Thromboprophylaxis with original enoxaparin in oncology patients
Т. 15, №1 (57)
CLL in the context of evidence-based medicine: how do international guidelines align with Ukrainian practice?
Authors: Kryachok I.A. Tytorenko I.B. Moroz Y.V. Т. 14, №4 (56)
Midazolam in modern anesthesiology and intensive care
Authors: Lisnyy I.I. Zakalska K.A. Т. 14, №4 (56)
Pembrolizumab vs Placebo as Adjuvant Therapy for High-Risk Stage II Melanoma: Long-Term Follow-Up, Rechallenge, and Crossover in KEYNOTE-716
Т. 14, №4 (56)
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Т. 14, №4 (56)

12345...Последняя »